ReviewDiscover oncology2025
Role of non-coding RNAs in radiotherapy sensitivity in non-small cell lung cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) is consistently the leading cause of cancer-related deaths worldwide. Radiotherapy is a crucial means of treating LC, and about 60-70% of LC patients require radiotherapy. However, radiotherapy resistance remains a significant challenge for treatment outcomes. Non-coding RNAs (ncRNAs) are widely engaged in multiple processes of tumorigenesis and progression. Extensive studies have shown that ncRNAs play an essential role in drug resistance in tumor therapy, including radiotherapy. Importantly, aberrantly expressed ncRNAs affect the efficacy of radiotherapy, whereas radiation response can result in the dysregulated expression of ncRNAs. Additionally, since the abnormal expression of ncRNAs in LC can respond to radiotherapy, circulating ncRNAs are also measurable in body fluids. Here, we describe the functions and mechanisms of ncRNAs in LC radiotherapy sensitivity and introduce the future directions and applications of ncRNAs in LC radiotherapy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.